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Abstract
HIV-1 Vif regulates viral infectivity by inhibiting the encapsidation of APOBEC3G (APO3G) through proteasomal degradation of the protein.
Here we compared various Vif proteins for their ability to induce APO3G degradation and rescue viral infectivity. We found that Vif expressed from
proviral vectors caused relatively inefficient degradation of APO3G in HeLa cells yet was very effective in inhibiting APO3G's antiviral activity. On
the other hand, Vif expressed autonomously from a codon-optimized vector caused very efficient APO3G degradation and also effectively inhibited
APO3G's antiviral effects. In contrast, a Vif chimera containing anN-terminal fluorescent tag efficiently inducedAPO3G degradation but was unable
to restore viral infectivity. The lack of a direct correlation between APO3G degradation and rescue of viral infectivity suggests that these two
properties of Vif are functionally separable. Our data imply that intracellular degradation of APO3Gmay not be the sole activity of Vif required for the
production of infectious virions from APO3G-expressing cells.
Published by Elsevier Inc.Keywords: Vif; APOBEC3G; Protein degradation; Virus–host interactionsIntroduction
Replication of HIV-1 in most primary cells and some
immortalized T cell lines is dependent on the expression of a
functional Vif protein. In the absence of Vif, virus replication is
restricted by several host deaminases, most notably APO-
BEC3G (APO3G) (Sheehy et al., 2002). In the absence of Vif,
APO3G is efficiently incorporated into virus particles where it
causes extensive hypermutation of the viral cDNA during
reverse transcription (Lecossier et al., 2003; Mangeat et al.,
2003; Mariani et al., 2003; Zhang et al., 2003). The conversion
of cytidine to deoxyuridine on the minus-strand cDNA results in
guanine to adenine changes on the viral plus-strand cDNA to
yield highly mutated viral genomes. Virus replication may be
inhibited through accumulation of mutations in the viral genome
or through degradation of the deaminated viral cDNA via a
cellular DNA repair mechanism (reviewed in Beard et al., 2003;⁎ Corresponding author. Fax: +1 301 402 0226.
E-mail address: kstrebel@nih.gov (K. Strebel).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2007.08.005Kavli et al., 2002). Alternatively, APO3G may inhibit virus
replication through deamination-independent mechanisms
(Bishop et al., 2006; Chiu et al., 2005; Guo et al., 2006;
Newman et al., 2005).
Vif is a 23-kDa basic protein that is expressed late during
infection. Previous immunocytochemical analyses revealed a
largely cytoplasmic localization of Vif (Goncalves et al., 1994;
Karczewski and Strebel, 1996; Simon et al., 1997). Vif is
efficiently incorporated into HIV virions during productive in-
fection through an interaction with viral genomic RNA and
associates with viral nucleoprotein complexes (Kao et al.,
2003a; Karczewski and Strebel, 1996; Khan et al., 2001; Liu et
al., 1995). In the presence of Vif, the steady-state levels of cell-
associated APO3G are reduced by 2- to 10-fold when compared
to Vif-negative controls (Conticello et al., 2003; Kao et al.,
2003b; Mariani et al., 2003; Marin et al., 2003; Mehle et al.,
2004b; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003).
Such Vif-induced reduction of intracellular APO3G has been
attributed to proteasome-dependent degradation of the protein
and requires a physical interaction of Vif and APO3G (Marin
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2003). Other studies, however, suggest that intracellular
degradation of APO3G may not be the sole mechanism by
which Vif neutralizes its antiviral activity (Kao et al., 2003b,
2004; Mariani et al., 2003; Mehle et al., 2004a).
The current study aimed at a more detailed characterization of
the effects of Vif on the stability of APO3G in transiently
transfected HeLa and 293T cells and its correlation with the
production of infectious virions. As part of this project, we
analyzed three different types of HIV-1 Vif, including (i) Vif
expressed from a proviral vector (A1-Vif); (ii) Vif expressed
from a codon-optimized vector in the absence of other viral
proteins (hVif); and (iii) Vif fused at its N-terminus to yellow
fluorescent protein (YFP-Vif). The YFP-Vif chimera was
previously found to efficiently induce proteasome degradation
of APO3G (Wichroski et al., 2005). Our own results are
consistent with these observations. In fact, in all of our
experiments, YFP-Vif and hVif were more effective in inducing
APO3G degradation than A1-Vif protein. Interestingly, despite
their different effects on APO3G stability, A1-Vif and hVif both
efficiently counteracted APO3G's antiviral activity. Surpris-
ingly, however, YFP-Vif was severely impaired in its ability to
direct the production of infectious HIV-1 particles fromAPO3G-
expressing cells. The lack of correlation between APO3G
degradation and infectivity of virus particles suggests that these
two functions of Vif can be separated. The efficiency with which
Vif induced APO3G degradation appeared to be dependent on
the expression system and was most pronounced when Vif was
expressed from autonomous (i.e. Tat- and Rev-independent)
expression vectors, e.g. hVif and YFP-Vif. The inefficient
degradation of APO3G by A1-Vif in HeLa cells was not due to
isolate-specific differences or the co-expression of additional
pNL-A1-encoded viral proteins. However, there were cell-type-
specific differences as APO3G degradation by A1-Vif was
somewhat more efficient in 293T cells than in HeLa cells. Taken
together our data demonstrate that the ability of HIV-1 Vif to
counteract the anti-viral effects of APO3G is not directly linked
to the efficiency of Vif-induced APO3G degradation by cellular
proteasomes. Our results also demonstrate that the functional
properties of Vif vary depending on the expression system used.
Importantly, our results suggest that intracellular degradation of
APO3G may not be the sole function of Vif required for the
production of infectious virions from APO3G-expressing cells.
These results are consistent with our recent identification of a
degradation resistant APO3G variant whose virus encapsidation
and antiviral activity was nonetheless efficiently controlled by
Vif (Opi et al., 2007).
Results
Variability in the efficiency of Vif-dependent APO3G
degradation
In the course of productive virus replication, Vif is expressed
from a partially spliced transcript and requires the activity of
Rev. Most of our previous studies on Vif involved the proviral
vector pNL-A1 that expresses Vif from an authentic, partiallyspliced Vif mRNA (Strebel et al., 1987). In this vector, Vif
expression is Rev dependent. Of note, pNL-A1 also expresses
other viral proteins including Tat, Rev, Nef, Vpr, Vpu, and Env.
To avoid the complexity of multigenic proviral vectors,
expression vectors have been developed that allow expression
of Vif in the absence of additional viral proteins (Goncalves
et al., 1994; Nguyen et al., 2004; Wichroski et al., 2005). In this
study, we employed two such vectors; (i) pcDNA-hVif
expressing Vif from a codon-optimized gene (Nguyen et al.,
2004) and (ii) pYFP-Vif expressing Vif fused at its N-terminus to
yellow fluorescent protein (Wichroski et al., 2005). Both of these
vectors allow for the Rev-independent expression of Vif and do
not encode additional viral proteins. The various Vif expression
vectors used in this study are schematically shown in Fig. 1A.
We first compared the relative effect of Vif expressed from
the various expression vectors on APO3G stability (Fig. 1B).
HeLa cells were transfected with pcDNA-Apo3G and either
pNL-A1vif(−) (Fig. 1B, Vif(−)), pNL-A1 (A1-Vif), pcDNA-
hVif (hVif), or pYFP-Vif (YFP-Vif) plasmid DNAs. Vif-
expressing vectors were provided in 5-fold excess over
APO3G-expressing vector (2.5 μg and 0.5 μg, respectively)
to maximize the impact of Vif on APO3G stability. To verify
proteasome-dependent degradation of APO3G, the proteasome
inhibitor epoxomicin (5 μM) was added to one set of each
sample 24 h after transfection. The second set remained
untreated. Cells were incubated for an additional 10 h prior to
cell lysis. Whole cell lysates were then analyzed by immuno-
blotting using a Vif-specific monoclonal antibody (Fig. 1B, α-
Vif) or an APO3G-specific polyclonal antibody (Fig. 1B, α-
APO3G). The APO3G blot was subsequently reprobed with an
antibody to α-tubulin to control for experimental variations
(Fig. 1B, α-tubulin). APO3G steady-state levels were quantified
by densitometric scanning of APO3G-specific bands and
expressed relative to the amount of APO3G observed in the
absence of Vif and inhibitor (Fig. 1C). As expected, the absence
of Vif resulted in stable expression of APO3G (Figs. 1B and C,
lanes 1). Epoxomicin treatment resulted in a small (5%) increase
in APO3G (Figs. 1B and C, lanes 2), presumably reflecting the
inhibition of the normal turnover of APO3G in transfected
HeLa cells. Expression of Vif from pNL-A1 resulted in a
moderate 20% reduction of the APO3G level (Figs. 1B and C,
lanes 3) that was partially reversed by the addition of
epoxomicin (Figs. 1B and C, lanes 4). In contrast, expression
of Vif from the codon-optimized vector (hVif) or in fusion with
yellow fluorescent protein (YFP-Vif) dramatically reduced
APO3G expression in the untreated samples (Figs. 1B and C,
lanes 5 and 7). The presence of epoxomicin significantly
stabilized APO3G levels in the hVif-expressing sample (Figs.
1B and C, lanes 6), verifying the involvement of proteasomes in
the cellular depletion of APO3G by hVif. Interestingly,
epoxomicin had very little effect on APO3G stability in YFP-
Vif expressing cells even though YFP-Vif itself was stabilized
by the drug (Figs. 1B and C, lanes 8). This result was
unexpected and could be explained by the incomplete inhibition
of proteasome-associated trypsin- and caspase-like proteolytic
activities by epoxomicin. Similar results were reported by
Wichroski et al. (2005), who found that at high levels of Vif
Fig. 1. Variability in the efficiency of Vif-induced APO3G degradation. (A) Vectors used for the expression of Vif in this study are schematically shown. The full-
length NL4-3 molecular clone, which is shown at the top for reference is a chimeric virus. Its 5′ half, including Vif, is derived from the NY5 HIV-1 isolate, while the
3′ half is derived from LAV (Adachi et al., 1986). The pNL-A1 vector was derived from pNL4-3 by removing its gag/pol/vif region and replacing it with a Vif
cDNA derived from the HIV-1 HXB2 isolate (Strebel et al., 1987). Aside from HXB2 vif, pNL-A1 encodes NL4-3 derived vpr, tat, rev, vpu, env, and nef genes but
lacks gag and pol genes. To express NL4-3 Vif in the context of pNL-A1, vif sequences in pNL-A1 were replaced via a PCR-based strategy by NL4-3 vif, resulting
in pNL-A1/43Vif. Plasmid pcDNA-hVif (Nguyen et al., 2004) encodes a codon-optimized HIV-1 Vif (NL4-3 isolate). Expression of Vif from this vector is Tat- and
Rev-independent and under the control of a CMV immediate early promoter. No other viral proteins are encoded by this vector. Plasmid pYFP-Vif encodes HIV-1
Vif (HXB2 isolate) fused to the C-terminus of yellow fluorescent protein (Wichroski et al., 2005). Protein expression is under the control of a CMV immediate early
promoter and is Tat- and Rev-independent. (B) HeLa cells were transfected with pcDNA-Apo3G (0.5 μg) and 2.5 μg of either pNL-A1vif(−) (lanes 1–2), pNL-A1
(lanes 3–4), pcDNA-hVif (lanes 5–6), or pYFP-Vif (lanes 7–8). One day later, cells were treated for 10 h with either DMSO (EPO−) or the proteasome inhibitor
epoxomicin (5 μM; (EPO+)). Whole cell lysates were analyzed by immunoblotting using antibodies to Vif (α-Vif) or APO3G (α-APO3G). The APO3G blot was
subsequently reprobed with an α-tubulin-specific monoclonal antibody (α-tubulin). (C) APO3G-specific bands in panel B were quantified by densitometric
scanning and plotted as percentage of the untreated vif(−) control, which was defined as 100% (lane 1). Lane numbers correspond to those in panel B.
Epo=epoxomicin.
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APO3G expression in transfected 293T cells. At lower
concentrations of YFP-Vif, proteasome inhibitor treatment
resulted in partial recovery of APO3G (data not shown). Thus,
when Vif expression vectors were provided at 5-fold excess over
the APO3G vector, hVif and YFP-Vif caused efficient degrada-
tion of APO3G while A1-Vif had only a modest effect on
APO3G stability. The observation that epoxomicin treatment
also increased the levels of Vif proteins in this experiment wasexpected since Vif itself is degraded by proteasomes (Fujita
et al., 2004).
APO3G degradation by hVif and YFP-Vif is dose dependent
and occurs at low levels of Vif
In the experiments shown in Fig. 1, Vif DNAwas provided at
5-fold excess over APO3G DNA. Next, the dose dependence of
Vif-induced APO3G degradation was analyzed (Fig. 2). For that
Fig. 2. Dose-dependent effect of Vif on cellular APO3G expression. (A) HeLa
cells were transfected with 1 μg of pcDNA-Apo3G (lanes 2–12) together with
increasing amounts (0.1, 0.5, 1.5 μg) of pNL-A1 (lanes 3–5), or pYFP-Vif (lanes
10–12). Amounts of transfected pcDNA-hVif were 0.2, 1, and 3μg (lanes 7–9) to
compensate for the lower expression of hVif from the codon-optimized vector
and to achieve comparable expression of the three Vif types in this experiment.
Vif-negative controls are shown in lanes 2 and 6. Total transfected DNA in all
samples was adjusted to 5 μg using pNL-A1vif(−) (lanes 2–5) or pcDNA3.1
vector DNA (lanes 6–12). The Vif(−) controls shown in lanes 2 and 6 each
contained 1 μg of pcDNA-Apo3G; however, the samples differ in that lane 2
contained 4μg of pNL-A1vif(−) while lane 6 contained 4 μg of pcDNA3.1 vector
DNA as filler DNA. These two controls were included because of the different
vector backbones used for Vif expression in this experiment. Lane 1 shows a
mock-transfected sample (no APO3G DNA). Cells were harvested 24 h after
transfection and whole cell lysates were analyzed by immunoblotting with
antibodies to Vif (α-Vif) or APO3G (α-APO3G). The APO3G blot was
subsequently reprobed with an antibody to tubulin to control for loading errors
(α-tubulin). (B) APO3G-specific bands frompanel Awere quantified. Results are
expressed as percentage of the respective vif-negative controls and were plotted
as a function of Vif levels. APO3G:Vif vector ratios are listed at the top and x-axis
values show the absolute amounts of transfected Vif vectors. Numbers in
parentheses refer to pcDNA-hVif DNA.
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pcDNA-Apo3G (1 μg) and increasing amounts (0.1, 0.5, or
1.5 μg) of plasmid DNA expressing A1-Vif (Fig. 2A, lanes 3–5)
or YFP-Vif (lanes 10–12). The ratios of APO3G:Vif vectors
were 10:1 (lanes 3 and 10), 2:1 (lanes 4 and 11), and 1:1.5 (lanes5 and 12). Amounts of transfected pcDNA-hVif DNA (lanes
7–9) were 2-fold higher than for A1-Vif and YFP-Vif (i.e. 0.2, 1,
and 3 μg, respectively) to compensate for the lower overall
expression of hVif from the codon-optimized vector when
compared to A1-Vif or YFP-Vif. Vif-negative vectors pNL-
A1vif(−) (lane 2) or pcDNA3.1 (lane 6) were included as
controls. Lane 1 is a mock-transfected control. Total amounts of
transfected DNA were adjusted to 5 μg by the addition of
appropriate amounts of Vif-negative pNL-A1vif(−) (Fig. 2A,
lanes 2–5) or empty pcDNA3.1 vector DNA (Fig. 2A, lanes
6–12). Whole cell lysates were prepared 24 h after transfection
and were analyzed by immunoblotting for the expression of Vif
(Fig. 2A, top panel) or APO3G (middle panel). The APO3G blot
was subsequently reprobed with an antibody to α-tubulin to
control for loading errors (bottom panel). APO3G signals were
quantified as described for Fig. 1C and the results are shown in
Fig. 2B. All three Vif proteins were expressed in a dose-de-
pendent manner and at comparable levels (Fig. 2A, α-Vif). As
before, A1-Vif had very little effect on APO3G expression at all
ratios tested (Fig. 2B, solid circles). In contrast, hVif (Fig. 2B,
open circles) and YFP-Vif (triangles) reduced APO3G expres-
sion in a dose-dependent manner and with comparable effi-
ciency. Even when APO3G vector was used at 5- or 10-fold
excess relative to hVif and YFP-Vif vectors, respectively,
APO3G expression was effectively reduced (Fig. 2B, 10:1).
Viral proteins encoded by pNL-A1 do not interfere with
Vif-induced APO3G degradation
Unlike pcDNA-hVif and pYFP-Vif, which encode only Vif,
the pNL-A1 vector encodes additional viral proteins, including
Tat, Rev, Nef, Env, Vpu, and Vpr (Strebel et al., 1987).
Interestingly, co-transfection of APO3G and pNL-A1vif(−)
plasmid DNAs in Fig. 2 resulted in slightly (b2-fold) increased
levels of APO3G (Fig. 2A, lane 2,α-APO3G)when compared to
APO3G co-transfected with pcDNA3.1 vector DNA (Fig. 2A,
lane 6, α-APO3G). It is therefore conceivable that pNL-A1-
encoded proteins affect APO3G expression or modulate the
ability of A1-Vif to induce APO3G degradation.
To assess the possible effect of Tat or other viral proteins
encoded by pNL-A1 on APO3G expression or stability, constant
levels of APO3G and hVif were expressed in the presence of
increasing amounts of pNL-A1vif(−) or pNL-A1. For that
purpose, HeLa cells were transfected with 0.5 μg of pcDNA-
Apo3G (Fig. 3, lanes 2–12) together with 0.5 μg of pcDNA-hVif
(lanes 3–12). In addition, increasing amounts (0.5, 1.5, 2.5,
3.5 μg, respectively) of pNL-A1vif(−) (Fig. 3, lanes 4–7) or
pNL-A1 (lanes 9–12) plasmid DNA were co-transfected. Total
transfected DNA in all samples was adjusted to 5 μg using
pcDNA3.1 vector DNA (lanes 2–12). Lanes 3 and 8 are replicate
samples and show the effect of hVif on APO3G stability in the
absence of co-transfected pNL-A1 vectors. Expression of
APO3G in the absence of hVif or A1-Vif is shown in lane 2.
Lane 1 is a mock-transfected control. Cells were harvested 24 h
after transfection and cell lysates were subjected to immunoblot
analysis using a Vif-specific monoclonal antibody (Fig. 3A,
α-Vif) or polyclonal antibodies to gp120 (α-Env) or APO3G
Fig. 3. Viral proteins encoded by pNL-A1 do not interfere with hVif-induced
APO3G degradation. (A) HeLa cells were either mock transfected (no DNA,
lane 1) or transfected with constant amounts of pcDNA-Apo3G (0.5 μg; lanes
2–12) and pcDNA-hVif (0.5 μg, lanes 3–12), together with increasing amounts
of pNL-A1vif(−) (lanes 4–7) or pNL-A1 DNA (lanes 9–12), as described in the
text. Cells were harvested 24 h post-transfection and whole cell lysates were
subjected to immunoblot analysis using antibodies to Vif (α-Vif), Env (α-Env),
or APO3G (α-APO3G). The APO3G blot was subsequently reprobed with
antibodies to tubulin to control for loading errors (α-tubulin). (B) APO3G
expression was quantified by densitometric scanning of the APO3G-specific
bands in panel A. Results were corrected for variations in tubulin levels and
plotted as percentage ofAPO3G recovered from theVif-negative sample (lane 2),
which was defined as 100%. Lane numbers correspond to those in panel A.
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monoclonal antibody to α-tubulin to control for loading errors
(α-tubulin). APO3G signals were quantified by densitometric
scanning of APO3G-specific bands and were corrected for
variations in tubulin signals. The results were plotted as
percentage of APO3G recovered relative to the vif-negative
control (lane 2), which was defined as 100% (Fig. 3B).
As expected, expression of hVif in the absence of pNL-A1
vectors led to a marked reduction of APO3G expression relative
to the vif-negative control (Figs. 3A and B, compare lane 2 with
lanes 3 and 8). The slight variation observed for APO3G levels
in the replicate samples shown in lanes 3 and 8 reflects ex-
perimental variation. Importantly, increasing amounts of pNL-
A1vif(−) (lanes 4–7) or pNL-A1 (lanes 9–12) had no detectable
effect on the ability of hVif to induce degradation of APO3G
(Fig. 3B). Expression of pNL-A1vif(−) and pNL-A1 vectors was
monitored by measuring Env expressed from these vectors using
an Env-specific polyclonal antibody (Fig. 3A, α-Env). As
expected, Env expression from pNL-A1vif(−) and pNL-A1 was
comparable and increased in a dose-dependent manner (Fig. 3A,
α-Env, compare lanes 4–7 and 9–12). Of note, expression of
hVif, which is under the control of a CMV immediate earlypromoter, was largely unaffected by increasing amounts of pNL-
A1vif(−) (Fig. 3A, α-Vif, lanes 4–7), suggesting that neither Tat
nor any of the other pNL-A1-encoded proteins significantly
affected CMV promoter activity in these experiments. As
expected, co-transfection of pNL-A1 led to a dose-dependent
increase in Vif expression (Fig. 3A, α-Vif, lanes 9–12).
Interestingly, despite the dramatic increase in Vif expression,
APO3G levels were not further reduced confirming that A1-Vif,
even at 7-fold excess of pNL-A1 DNA over pcDNA-hVif DNA,
was unable to exacerbate the hVif-induced degradation of
APO3G (Fig. 3B, compare lane 8 with lanes 9–12). The finding
that the presence of increasing amounts of pNL-A1vif(−) or
pNL-A1 had no effect on the ability of hVif to induce APO3G
degradation implies that none of the pNL-A1 encoded proteins
modulates Vif function to a significant extent and suggests that
the inability of A1-Vif to efficiently induce degradation of
APO3G in Figs. 1 and 2 is a cis-effect and not due to the
expression of extraneous viral proteins such as Tat or Nef.
Comparative analysis of A1-Vif induced APO3G degradation
in HeLa and 293T cells
Previous studies have reported more pronounced effects of
A1-Vif on APO3G degradation than observed in our hands
(Mehle et al., 2004b; Stopak et al., 2003;Wichroski et al., 2005).
The reason for this discrepancy is unclear but could be due to (i)
cell-type-specific differences (most labs use 293T cells as
opposed to HeLa cells used in our study); (ii) differences in the
relative ratio of Vif:APO3G vectors; or (iii) differences in the
APO3G vector itself since the APO3G construct used in our
study has two amino acid differences (S162N and D370Y)
relative to the published sequence for APO3G (Kao et al.,
2003b). To address these issues, we performed a side-by-side
analysis of our APO3G clone (referred to here as APO3G-NY)
with a variant (referred to here as APO3G wt), in which the two
residues were changed to the published sequence. Parallel
experiments were performed in HeLa and 293Tcells. HeLa cells
(Figs. 4A and B) or 293T cells (Figs. 4C and D) were co-
transfected with pNL-A1 (Vif+) or pNL-A1vif(−) (Vif−) and
either pcDNA-APO3Gwt-myc (APO3Gwt) or pcDNA-APO3G-
NY-myc (APO3G-NY) using various ratios of Vif:APO3G
vectors as indicated in Fig. 4. Amounts of transfected DNA are
listed in the legend to Fig. 4. Cells were harvested 36 h following
transfection and cell lysates were analyzed by immunoblotting
with antibodies to Vif (Figs. 4A and C, top panels) or APO3G
(Figs. 4A and C, middle panels). The APO3G-specific blots were
subsequently reprobedwith a tubulin-specific antibody to control
for loading errors (Figs. 4A and C, lower panels). APO3G-
specific bands were quantified by densitometric scanning and
signals for APO3G from Vif-positive samples were expressed as
percentage of the signal observed for the corresponding Vif-
negative sample (Figs. 4B and D). In HeLa cells, the effects of
A1-Vif on APO3G wt or APO3G-NY stability were modest but
dose dependent. At 10-fold excess of transfected Vif vector over
APO3G vector, we noticed a∼30–40% reduction of APO3G wt
and APO3G-NY levels while at 1:1 transfection ratios, the effect
of A1-Vif on APO3G wt or APO3G-NY stability was virtually
Fig. 4. Comparative analysis of A1-Vif-induced APO3G degradation in HeLa and 293Tcells. Hela cells (A and B) or 293Tcells (C and D) were transfected with 2.5 μg
of either pNL-A1 (Vif+) or pNL-A1vif(−) vectors (Vif−), together with decreasing amounts (2.5, 0.83, 0.25 μg) of vectors encoding APO3G wt or APO3G-NY, to
achieve the plasmid ratios as indicated in the figure. Transfected DNA amounts in all samples were adjusted with empty pcDNA3.1 vector to 5 μg total DNA. (A and C)
Cells were harvested 36 h post-transfection and cell lysates were subjected to immunoblot analysis using antibodies to Vif and APO3G. The APO3G blot was
subsequently reprobed with an antibody to α-tubulin. Proteins are identified on the right. (B and D) APO3G-specific bands were quantified by densitometric scanning
and the amounts of APO3G recovered from Vif-expressing samples were plotted as percentage of the signals obtained for the corresponding Vif-negative samples.
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APO3G stability were somewhat more pronounced in 293Tcells.
For instance, transfection of Vif and APO3G vectors at a 10:1
ratio reduced APO3G levels ∼4- to 5-fold (Fig. 4D). There was
no significant difference, however, between APO3G wt and
APO3G-NY with respect to protein expression and sensitivity to
A1-Vif in HeLa or 293T cells. Thus, although 293T cells
appeared to be more permissive overall to Vif-induced APO3G
degradation, the two amino acid difference between APO3G wt
and APO3G-NY did not alter their sensitivity to Vif.
A1-Vif and hVif but not YFP-Vif proteins inhibit the antiviral
activity of APO3G
The ability of hVif and YFP-Vif to efficiently reduce cellular
APO3G levels in the experiment shown in Fig. 2 predicted thathVif and YFP-Vif would be highly effective and presumably
more efficient than A1-Vif in inhibiting the antiviral activity of
APO3G. To test this hypothesis, vif-defective NL4-3 virus was
produced in the presence of constant amounts of APO3G and
increasing amounts of A1-Vif, hVif, or YFP-Vif as detailed in
the legend to Fig. 5. The ratios of Vif to APO3G vectors tested
here were 1:10 (Fig. 5, lanes 3, 7, 10), 1:2 (lanes 4, 8, 11), and
1.5:1 (lanes 5, 9, 12). As a control, vif-defective NL4-3 virus was
produced without exogenous Vif in the absence (lane 1) or
presence (lane 2) of APO3G. Virus-containing supernatants
from transfected cultures were collected 48 h after transfection,
normalized for reverse transcriptase (RT) activity, and used for
the infection of LuSIV indicator cells (Fig. 5). Relative
infectivity of the viruses was determined by measuring the
virus-induced expression of luciferase in the LuSIV cells 24 h
later. The infectivity of vif-defective virus produced in the
Fig. 6. The inability of YFP-Vif to restore viral infectivity is not due to a non-
specific inhibitory effect of YFP-Vif. Vif-defective viruses were produced in
HeLa cells by transfection with pNL4-3vif(−) (3 μg) in the presence of
increasing amounts of YFP-Vif (0.1, 0.5, 1.5 μg) and in the absence (lanes 3–5)
or presence (lanes 6–8) of 1 μg APO3G vector. Note that the ratio of Vif to
APO3G vectors in lanes 6–8 was the same as in Fig. 5 (lanes 10–12). Vif-
defective viruses produced in the absence (lane 1) and presence (lane 2) of
APO3G were included as controls. (A) Cells and virus-containing supernatants
were harvested 48 h after transfection and processed for immunoblotting as
described in Materials and methods. Filters were probed with antibodies to
APO3G or Vif, or were reacted with an HIV-positive patient serum for the
detection of capsid protein (CA). Proteins are identified on the right. (B) Virus-
containing supernatants were normalized for reverse transcriptase activity and
used for the infection of LuSIV indicator cells as in Fig. 5. Relative luciferase
units (RLU) are shown. A log scale was chosen to visualize the small increase in
viral infectivity by YFP-Vif. Error bars reflect the standard error from duplicate
infections.
Fig. 5. A1-Vif and hVif efficiently inhibit the APO3G antiviral activity. (A)
HeLa cells were transfected with constant amounts of vif-defective pNL4-3
(3 μg) and pcDNA-Apo3G DNA (1 μg), together with increasing amounts of
A1-Vif, hVif, or YFP-Vif (0.1 μg: lanes 3, 7, 10; 0.5 μg: lanes 4, 8, 11; 1.5 μg:
lanes 5, 9, 12). Cell-free, virus-containing supernatants were harvested 48 h
post-transfection, normalized for reverse transcriptase activity and used to infect
LuSIV indicator cells. Vif-defective viruses produced in the absence (lane 1) and
presence (lane 2 and 6) of APO3G were included as controls. Virus-induced
activation of luciferase was determined 24 h later in a standard luciferase assay.
Results were calculated relative to the signal obtained with vif-defective virus
produced in the absence of APO3G (lane 1), which was defined as 100%. Error
bars reflect standard error calculated from multiple independent experiments
(n=number of independent analyses).
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expected, the infectivity of vif-defective viruses produced in the
presence of APO3G was near background levels (Fig. 5, lanes 2
and 6). In contrast, expression of A1-Vif (lanes 3–5) and hVif
(lanes 7–9) increased viral infectivity in a dose-dependent
manner. The drop in infectivity at high levels of A1-Vif (Fig. 5,
lane 5) is consistent with our previous observation that high-
level expression of Vif can inhibit viral infectivity (Akari et al.,
2004). Surprisingly, YFP-Vif did not restore viral infectivity to a
significant extent despite its potent effect on APO3G stability
(see Figs. 1, 2, and 6A). The results shown in Fig. 5 were derived
from multiple independent experiments. In particular, experi-
ments involving YFP-Vif were performed 19 times because of
the unexpected result.
To control for possible toxic effects of YFP-Vif that could
affect viral infectivity independent of APO3G, HeLa cells were
transfected with vif-defective NL4-3 together with increasing
amounts of YFP-Vif either in the absence (lanes 3–5) or
presence of APO3G (Fig. 6A, lanes 6–8). Vif-defective NL4-3
produced in the absence (lane 1) or presence of APO3G (lane 2)
but without YFP-Vif were included as controls. Intracellular
protein expression and virus production were monitored by
immunoblotting (Fig. 6A). As predicted, increasing levels of
YFP-Vif correlated with decreasing amounts of intracellular
APO3G and was paralleled by decreasing levels of virus-
associated APO3G. Importantly, however, small amounts of
virus-associated APO3G were detectable even at the highest
level of YFP-Vif tested. Also, YFP-Vif had a small butidentifiable effect on expression of viral protein and release of
viral particles (Fig. 6A, CA; compare lanes 3–5 and 6–8). This
effect was independent of APO3G and the Vif portion of the
YFP-Vif chimera and was seen with other YFP- or GFP-tagged
expression constructs (Khan et al., 2005 and data not shown).
Viral infectivity was determined as described for Fig. 5.
Consistent with the results from Fig. 5, expression of increasing
amounts of YFP-Vif in the presence of APO3G only modestly
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however, YFP-Vif did not significantly affect infectivity of viral
particles in the absence of APO3G (Fig. 6B, lanes 3–5). These
results rule out that the lack of infectivity of virus produced in the
presence of APO3G and YFP-Vif was caused by a non-specific
inhibitory or toxic effect of YFP-Vif.
Discussion
Since the identification of APO3G as a potent Vif-sensitive
antiviral host factor (Sheehy et al., 2002), a tremendous effort
has been made to understand how Vif counteracts the inhibitory
effect of APO3G and other cellular cytidine deaminases. Two
key observations have aided in this effort: (i) Vif was found to
inhibit the packaging of APO3G into viral particles (Kao et al.,
2003b; Mariani et al., 2003; Marin et al., 2003; Mehle et al.,
2004b; Sheehy et al., 2003; Stopak et al., 2003) and (ii) Vif
reduced the cellular steady-state levels of APO3G through
proteasomal degradation (Conticello et al., 2003; Marin et al.,
2003; Mehle et al., 2004b; Sheehy et al., 2003; Stopak et al.,
2003; Yu et al., 2003). Because packaging of APO3G was found
to be directly correlated with cellular expression levels, it
follows that the Vif-induced reduction of cellular APO3G
contributes directly to the exclusion of APO3G from HIV-1
particles. On the other hand, several reports noted that the
inhibition of APO3G encapsidation by Vif can be more
pronounced than the reduction of intracellular steady-state
levels (Kao et al., 2003b; Mariani et al., 2003), suggesting
additional degradation-independent mechanism(s) of interfer-
ence with APO3G packaging. Indeed, we previously reported
that intracellular depletion of APO3G by Vif is not a prerequisite
for the rescue of viral infectivity (Kao et al., 2004). The results
from the current study support these observations by demon-
strating that a moderate reduction of intracellular APO3G levels
by A1-Vif was sufficient to overcome the inhibitory effects of
APO3G with similar efficiency as hVif, which efficiently
depleted cellular APO3G. These results lead us to conclude
that intracellular depletion of APO3G and rescue of viral
infectivity are not necessarily linked but may in fact be separable
functions of Vif. These conclusions are supported by our recent
identification and characterization of an APO3Gmutant that was
resistant to Vif-induced degradation but whose antiviral activity
and viral encapsidation were, nonetheless, efficiently controlled
by Vif (Opi et al., 2007). Our conclusions are further supported
by the recent finding that mutation of a serine residue at position
144 in Vif (S144A) did not impair its effect on APO3G
expression yet severely impaired its ability to govern the
production of infectious viruses from APO3G-expressing cells
(Mehle et al., 2004a).
It is unclear why YFP-Vif, despite substantial degradation
of cellular APO3G, did not restore viral infectivity. We can
rule out non-specific cytotoxicity of YFP-Vif (Fig. 6). It is
important to note, however, that despite extensive degradation
in YFP-Vif expressing cells, small amounts of APO3G
remained detectable in cell-free virus preparations even at
the highest level of YFP-Vif (Fig. 6A). It is conceivable that
such residual amounts of virus-associated APO3G aresufficient to inhibit viral infectivity. Indeed, a recent study
suggested that only a few copies of APO3G per virion were
required to inhibit HIV-1 replication (Xu et al., 2007). It should
be pointed out, however, that even viruses produced in the
presence of A1-Vif or hVif invariably contained small amounts
of virus-associated APO3G (data not shown). Whether such
levels were below a critical threshold is unclear. Alternatively,
it is possible that A1-Vif and hVif proteins have functional
properties required to control residual virus-associated APO3G
that were lost in YFP-Vif. These questions will be addressed in
future studies.
It also remains to be investigated why YFP-tagged Vif and
hVif are more effective in inducing APO3G degradation than
A1-Vif. The difference in APO3G degradation cannot be ex-
plained by relative Vif protein levels since in the experiment
shown in Fig. 2 all Vif proteins were expressed at very similar
levels. Also, we can rule out isolate-specific differences since
NL4-3 Vif and HXB2 Vif were both inefficient in inducing
APO3G degradation when expressed in the backbone of pNL-
A1 (data not shown) but were equally efficient when expressed
from autonomous vector systems (Fig. 2, cf. hVif and YFP-Vif).
Finally, we ruled out possible modulating effects on APO3G
degradation by pNL-A1-encoded viral proteins (e.g. Tat, Rev,
Nef, Env, Vpr, or Vpu; Fig. 3). One important difference
between A1-Vif and hVif or YFP-Vif vectors is the structure of
the Vif-encoding mRNA. A1-Vif are expressed from a Rev-
dependent mRNA that requires the cellular Crm-1 pathway for
nuclear export (for review, see Strebel and Bour, 1999). In
contrast, hVif and YFP-Vif mRNAs are Rev-independent and
are exported from the nucleus via a Crm-1 independent
pathway. It is possible that differences in mRNA export affect
the cellular targeting of Vif. The idea that differences in mRNA
targeting may translate into different functional properties of the
encoded protein is not unprecedented as it was previously
reported that assembly and release of HIV capsids from rodent
cells was influenced by differences in the mode of nuclear
mRNA export (Swanson et al., 2004).
Our finding that A1-Vif appeared to be more effective in
targeting APO3G into a proteasomal degradation pathway in
293T cells when compared to HeLa cells (Fig. 4) is interesting
and could explain some of the existing differences between our
observations regarding A1-Vif and APO3G in HeLa cells and
those reported by others using 293T cells (Mehle et al., 2004b;
Wichroski et al., 2005; Xu et al., 2004). It is unclear why 293T
cells seem more susceptible to APO3G degradation by A1-Vif.
However, 293T cells are generally believed to be more
susceptible to transfection. Because the Vif effect is dose-
dependent, a simple explanation would be that Vif is more
efficiently expressed on a per-cell level in 293T cells.
Alternatively, it is possible that HeLa and 293T cells exhibit
differences in the intracellular targeting of A1-Vif. In analogy to
our discussion on the differential effects of A1-Vif and hVif in
HeLa cells, one could speculate that A1-Vif expressed in 293T
cells is more efficiently targeted to intracellular compartment(s)
relevant to APO3G degradation. The functional relevance of the
more efficient APO3G degradation by A1-Vif in 293T cells
versus HeLa cells remains unclear, however, especially since
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presence of Vif are fully infectious.
The question of how Vif might prevent the packaging of
APO3G into viral particles under conditions of little or no
APO3G degradation remains under active investigation. We
have reported that both Vif and APO3G are packaged through
specific interactions with viral genomic RNA (Khan et al., 2001,
2007, 2005). It is therefore conceivable that Vif inhibits the
packaging of APO3G through a competitive mechanism by
binding to a common packaging signal on the viral RNA.
Alternatively, intracellular Vif–APO3G interactions could lead
to sequestration of the proteins in a cellular compartment that
prohibits their packaging into viral particles without prior
degradation. In such a scenario, the fate of APO3G (i.e.
degradation vs. sequestration) could depend on where in the cell
or when after synthesis the Vif–APO3G interaction occurs.
APO3G has the propensity to assemble into highmolecular mass
ribonucleoprotein complexes (Chiu et al., 2005; Gallois-
Montbrun et al., 2007; Kozak et al., 2006). It is conceivable
that Vif accelerates this process and experiments are ongoing to
study the relative contribution of Vif to the assembly of APO3G
into high molecular mass complexes.
Materials and methods
Cell culture and transfections
HeLa cells were propagated in Dulbecco's modified Eagles
medium (DMEM) containing 10% fetal bovine serum. LuSIV
cells are derived from CEMx174 cells and contain a luciferase
indicator gene under the control of the SIVmac239 LTR. These
cells were obtained through the NIH AIDS Research and Refe-
rence Reagent Program and were maintained in complete RPMI
1640 medium supplemented with 10% FBS and hygromycin B
(300 μg/ml). For transfection of HeLa cells, cells were grown in
25 cm2 flasks to about 80% confluency. Cells were transfected
using LipofectAMINE PLUS™ (Invitrogen, Carlsbad CA)
following the manufacturer's recommendations. A total of
5 μg of plasmid DNA per 25 cm2 flask was generally used.
Where appropriate, empty vector DNA (pcDNA3.1(−)MycHis
(Invitrogen)) or vif-defective vector DNA (pNL-A1vif(−)) was
used to adjust total DNA amounts. Cells were harvested 24 to
48 h post-transfection.
Antibodies
A peptide antibody to human APO3G was prepared by
immunizing rabbits with KLH-coupled peptides corresponding
to residues 367 to 384 of humanAPO3G.Amonoclonal antibody
toVif (MAb #319) was used for all immunoblot analyses andwas
obtained from Michael Malim through the NIH AIDS Research
and Reference Reagent Program (Cat No: 6459). A monoclonal
antibody to alpha-tubulin (T-9026; Sigma-Aldrich, St. Louis
MO) was used as a loading control. An HIV-positive patient
serum was used for the identification of HIV-1 capsid (CA)
protein. An HIV-1 Env-specific antibody was produced by
immunizing rabbits with purified recombinant gp120.Plasmids
Construction of the vif-defective pNL4-3 vif(−) vector
was described previously (Karczewski and Strebel, 1996).
Expression vectors pNL-A1 for the expression of HXB2 Vif in a
proviral backbone and its vif-defective variant, pNL-A1vif(−),
have been described previously (Khan et al., 2001; Strebel et al.,
1987). Both vectors express additional HIV-1 proteins including
Vpr, Tat, Rev, Vpu, Env, and Nef. The construction of pcDNA-
hVif for the expression of NL4-3 Vif from a codon-optimized
gene under the transcriptional control of a CMV promoter has
been described elsewhere (Nguyen et al., 2004). The pYFP-Vif
vector for the expression of Yellow Fluorescent Protein (YFP)-
tagged HXB2 Vif under the control of a CMV promoter was a
gift of Tariq Rana (Wichroski et al., 2005). The vector for the
expression of APO3G carrying a C-terminal myc epitope tag,
pcDNA-Apo3Gmyc, has been described previously (Kao et al.,
2003a). A variant, pcDNA-Apo3G, expressing untagged
APO3G was used for all experiments described in this study
except Fig. 5 and was constructed by insertion of a stop codon at
the end of the APO3G gene in pcDNA-Apo3Gmyc (Opi et al.,
2006). Plasmid pcDNA-APO3Gwt-myc is a derivative of
pcDNA-Apo3Gmyc and was created by site-specific mutagen-
esis to introduce N162S and Y370D changes that make it
identical to the published sequence for CEM15 (Sheehy et al.,
2002; Genbank NM_021822 and AF182420).
Immunoblotting
For immunoblot analysis of intracellular proteins, whole
cell lysates were prepared as follows: Cells were washed once
with PBS, suspended in PBS and mixed with an equal volume
of sample buffer (4% sodium dodecyl sulfate, 125 mM Tris–
HCl, pH 6.8, 10% 2-mercaptoethanol, 10% glycerol, and
0.002% bromphenol blue). To analyze virus-associated
proteins, cell-free filtered supernatants from transfected HeLa
cells (5–7 ml) were pelleted (75 min, 35,000 rpm) through a
20% sucrose cushion (4 ml) in an SW41 rotor. The con-
centrated virus pellet was suspended in PBS and mixed with
an equal volume of sample buffer. Proteins were solubilized by
heating 10 to 15 min at 95 °C. Cell and virus lysates were
subjected to SDS–PAGE; proteins were transferred to PVDF
membranes and reacted with appropriate antibodies as
described in the text. Membranes were then incubated with
horseradish peroxidase-conjugated secondary antibodies
(Amersham Biosciences, Piscataway, NJ) and proteins were
visualized by enhanced chemiluminescence (ECL, Amersham
Biosciences).
Virus preparation
Virus stocks were prepared by transfection of HeLa cells with
appropriate plasmid DNAs. Virus-containing supernatants were
harvested 24 to 48 h after transfection. Cellular debris was
removed by centrifugation (5 min, 1500 rpm) and clarified
supernatants were filtered (0.45 μM) to remove residual cellular
contaminations. Filtered virus stocks were further purified by
338 S. Kao et al. / Virology 369 (2007) 329–339pelleting through a 20% sucrose cushion (75 min, 4 °C at
35,000 rpm in an SW41 rotor).
Viral infectivity assay
To determine viral infectivity, virus stocks were normalized
for equal reverse transcriptase activity and used to infect 5×105
LuSIV cells (Roos et al., 2000) in a 24-well plate in a total
volume of 1.2 to 1.4 ml. Infection was allowed for 24 h at 37 °C.
Cells were then harvested and lysed in 150 μl of Promega 1×
reporter lysis buffer (Promega, Madison, WI). To determine the
luciferase activity in the lysates, 50 μl of each lysate was
combined with luciferase substrate (Promega) by automatic
injection and light emission was measured for 10 s at room
temperature in a luminometer (Optocomp II, MGM Instruments,
Hamden, CT).
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